Gilmore is President and Chief Executive Officer of Editas Medicine and a member of the Editas Board of Directors. He joined Editas Medicine in June 2022.
Gilmore brings to Editas more than 20 years of experience in genetic medicine, neurobiology, and clinical development. Gilmore also has a track record of driving and leading several of biotech’s most successful clinical programs and achieving marketing approvals for several medicines, including Amondys®, Vyondys®, Spinraza®, Plegridy®, and Tecfidera®.
Gilmore most recently served as Executive Vice President of R&D and Chief Medical Officer at Sarepta Therapeutics. During his tenure at Sarepta, he led the R&D leadership team accountable across the value chain from creating and driving discovery, preclinical and clinical development, and global regulatory strategy of its RNA and gene therapeutic portfolio through to Medical Affairs support of the marketed products. Prior to that, Gilmore held several leadership roles at Biogen over a 15-year period, most recently serving as Senior Vice President responsible for all late-stage clinical development. During his tenure at Biogen, Gilmore oversaw development programs for rare disease, gene and cell therapy, neuromuscular disease, pain, multiple sclerosis, acute neurology, movement disorders, and Alzheimer’s disease.
Gilmore currently serves on the Board of Directors at UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging.
Gilmore received a Bachelor of Medicine degree from University College Dublin, a Master of Medical Sciences degree from Harvard University and completed his Neurology Residency training at Massachusetts General Hospital. He is licensed to practice medicine in the state of Massachusetts.
What is Gilmore Neil O'neill's net worth?
The estimated net worth of Gilmore Neil O'neill is at least $653.88 thousand as of December 3rd, 2025. Dr. O'neill owns 269,087 shares of Editas Medicine stock worth more than $653,881 as of December 4th. This net worth approximation does not reflect any other assets that Dr. O'neill may own. Learn More about Gilmore Neil O'neill's net worth.
How do I contact Gilmore Neil O'neill?
Has Gilmore Neil O'neill been buying or selling shares of Editas Medicine?
In the last ninety days, Gilmore Neil O'neill has sold $12,046.45 of Editas Medicine stock. Most recently, Gilmore Neil O'neill sold 5,603 shares of the business's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $2.15, for a transaction totalling $12,046.45. Following the completion of the sale, the chief executive officer now directly owns 269,087 shares of the company's stock, valued at $578,537.05. Learn More on Gilmore Neil O'neill's trading history.
Who are Editas Medicine's active insiders?
Are insiders buying or selling shares of Editas Medicine?
During the last year, insiders at the sold shares 8 times. They sold a total of 28,941 shares worth more than $57,219.74. The most recent insider tranaction occured on December, 3rd when EVP Linda Burkly sold 713 shares worth more than $1,532.95. Insiders at Editas Medicine own 2.1% of the company.
Learn More about insider trades at Editas Medicine. Information on this page was last updated on 12/3/2025.
